Syngene is excited to be participating in Bio International Convention, by far the largest and most popular pharma event of the year. We are among the few contract research development and manufacturing organizations (CRDMOs) offering integrated and end-to-end drug discovery, development, and manufacturing services across biologics and small molecules.
Based out of India, we will support you as a single-source partner with a broad suite of capabilities, allowing you to manage projects centrally, unhindered by logistical/shipping delays or dependencies on third-party deliverables. We will enable timely completion of projects, efficiency, and cost savings.
Throughout our 30 years of history, we have worked with well over 1000 companies, and are currently the preferred partner to 400+ global organizations. We are also co-authors of 400+ customer patents.
The Syngene Advantage for Biologics Development and Manufacturing
140+ successful projects
25+ INDs enabled
Top 15 biopharma companies as clients
Trusted
- Transparency with real-time data sharing
- IT systems fully compliant with the ISO 27001 Information Security Standard
- IP exclusivity to clients
Capable
- US FDA, EMA, MHRA approved manufacturing facilities
- 28KL single-use bioreactor capacity and sterile fill-finish capacity of 1 million vials/day
- Experienced in diverse modalities like mAbs, bispecifics, ADCs, pDNA, mRNA
Meet our Experts
Alex Del Priore
Senior Vice President – Manufacturing Services
Jeffry Wong
VP Biologics
Anjan Chakrabarti
VP Discovery Services
Simon Hickling
VP Development Services
Syngene International Limited. All rights reserved © 2024